4/A: Quoin Pharmaceuticals Amends COO's Stock Option Grant, Correcting Previously Understated ADS Amount

Quoin Pharmaceuticals, Ltd. filed an amended Form 4 to correct an inadvertent understatement in the number of American Depositary Shares underlying a stock option granted to Chief Operating Officer Denise P. Carter.

Summary

• Quoin Pharmaceuticals, Ltd. filed a Form 4/A on June 13, 2025, to amend a previously filed Form 4 from June 2, 2025.
• The amendment corrects an inadvertent understatement in the number of American Depositary Shares (ADSs) underlying a share option granted to Denise P. Carter, the Chief Operating Officer and Director.
• The original option grant occurred on May 29, 2025.
• The corrected number of ADSs underlying the option is 42,857.
• The exercise price for the option is $9.07 per ADS.
• Each ADS represents thirty-five ordinary shares of Quoin Pharmaceuticals.
• The option vests in four annual installments: 20% on May 29, 2026, 20% on May 29, 2027, 20% on May 29, 2028, and 40% on May 29, 2029.
• The option is set to expire on May 29, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the company is correcting an administrative error, demonstrating transparency and compliance. The initial error is a minor negative, but the prompt correction mitigates its impact.

Positives

• The company is demonstrating transparency and adherence to reporting requirements by promptly correcting an administrative error in a regulatory filing.
• The correction ensures accurate disclosure of executive compensation, which is beneficial for investor clarity.

Negatives

• The initial filing contained an administrative error, indicating a potential oversight in the reporting process.

Risks

• No specific business or operational risks are mentioned in this Form 4/A filing. The only 'risk' identified is the administrative error in the initial filing, which has now been corrected.

Future Outlook

The document details the vesting schedule for the granted share option, indicating future dates when portions of the option will become exercisable for the Chief Operating Officer.

Management Comments

• "On June 2, 2025, the reporting person filed a Form 4 which inadvertently understated the number of ADSs underlying the option granted to the reporting person on May 29, 2025."

Industry Context

This filing is a routine amendment to an insider trading report (Form 4), correcting a detail about executive compensation. It does not provide information relevant to broader industry trends or competitive dynamics within the pharmaceutical sector.

Comparison to Industry Standards

• Not applicable. This document is a regulatory filing correcting an administrative error in an executive's stock option grant, not a performance report that can be compared to industry benchmarks or specific companies/projects.

Related Party Transactions

• The document details a share option grant to Denise P. Carter, who is the Chief Operating Officer and a Director of Quoin Pharmaceuticals, Ltd., making this a transaction with a related party.

Stakeholder Impact

• Shareholders: The correction provides accurate information regarding executive compensation, ensuring transparency in company disclosures.
• Management/Employees: Denise P. Carter's compensation details are accurately reflected, which is important for internal record-keeping and maintaining trust regarding compensation transparency.

Next Steps

• 20% of the share option will vest on May 29, 2026.
• 20% of the share option will vest on May 29, 2027.
• 20% of the share option will vest on May 29, 2028.
• 40% of the share option will vest on May 29, 2029.
• The share option will expire on May 29, 2035.

Key Dates

Keywords

Quoin Pharmaceuticals, QNRX, SEC Form 4/A, Stock Option, American Depositary Shares, ADS, Beneficial Ownership, Insider Trading, Executive Compensation, Denise P. Carter, Amendment